Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

biOasis Technologies Ord Shs V.BTI.H

Alternate Symbol(s):  BIOAF

Healthcare Biotechnology
Bioasis Technologies Inc. is a Canada-based biopharmaceutical company focused on research and development of technologies and products intended for the treatment of patients with nervous system, including central nervous system, diseases and disorders. The Company is engaged in the development of its xB 3 platform, which is a peptide-based technology, for the transport of therapeutic agents, in particular biological products, across the blood-brain barrier (BBB). It is focused on both orphan drug indications, including brain cancers, and rare genetic neurodegenerative diseases and neuroinflammatory conditions. The Company is also focused on its Epidermal Growth Factor (EGF) platform for treating rare and orphan neurodegenerative and neuroinflammatory disorders. EGF is a protein that stimulates cell growth and differentiation, notably for myelin producing cells. Its development programs include xB3-001: Brain Metastases, xB3-002: Glioblastoma and xB3-007: Neurodegenerative Disease.


TSXV:BTI.H - Post by User

biOasis Technologies Ord Shs > One more thing ......
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(19)
•••
Comment by fuzzyjron Dec 15, 2022 2:47pm
136 Views
Post# 35173959

RE:RE:RE:RE:One more thing ......

RE:RE:RE:RE:One more thing ......"The most imortant reason why $MTP  bought bioaf is because it is developing xB3, a platform technology for the transport of therapeutic agents across the blood-brain barrier (BBB)"

i agree, its just going to take even more time - yuk i know - could be 2-3 years for big hit but in the meantime & after the dust settles here we could easily be up 3-4 times from this level in 3-6 months from now - heck could be tens times higher in a year - i don't know but ya cant get much closer to da bottom unless ya shut the doors. Science is a slow moving beast & being a shareholder can make a fella half goofy at times - found this out the hard way :(

 like i heard a old timer say long ago "ya just going to lay there & bleed & whine or r ya going to rise up & get back in the fight" since then i've always done my best to gather myself & make it back up with even more fire in my belly

the choice is yours
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities